A Therapeutic Update on the Management of Patients with Atopic Dermatitis

After many years of little movement in new therapies for patients with atopic dermatitis (AD), significant growth in researching the pathogenesis of AD has resulted in a better understanding of its causes, which has led to new protein targets for novel monoclonal antibodies (mABs). Often diagnosed in infancy, AD can persist into adulthood, affecting 3% to 5% of adults in the United States. Approximately 20% of children and adult patients have been diagnosed with moderate-to-severe AD. For this patient population, these latest advances continue to offer hope, as the current standard of care, which largely centers on symptom management, is suboptimal. This enduring video-based roundtable activity provides the latest updates on AD, including data on emerging and novel treatment options. Expert clinical faculty will also discuss the latest research in AD presented at the 41st Annual Hawaii Dermatology Seminar.


The goal of this activity is to provide up-to-date comprehensive information for clinicians on the treatment and management of patients with AD.


This enduring activity is intended for dermatologists, allergists, immunology specialists, internists and primary care providers, including physicians, nurse practitioners, physician assistants, and other healthcare providers who are responsible for the diagnosis, treatment, or management of patients with AD. No prerequisites required.



Upon completion of this activity, participants will be better able to do the following:

  1. Evaluate the current standard of care for treating AD and its limitations in treating moderate-to-severe AD.
  2. Describe key immune pathways associated with AD and the role of these pathways in treatment development.
  3. Integrate the latest information on new and emerging advancements in the treatment of patients with AD.


Lawrence Eichenfield, MD (Chair)
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
Chief, Pediatric and Adolescent Dermatology
University of California
San Diego School of Medicine
San Diego, California

Jonathan I. Silverberg, MD, PhD, MPH
Assistant Professor of Dermatology
Medical Social Sciences and Preventive Medicine
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine Multidisciplinary Eczema Center
Chicago, Illinois

Linda Stein-Gold, MD
Director of Dermatology Research
Division Head, Dermatology
Department of Dermatology
Henry Ford Hospital
Detroit, Michigan

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Relationship Identified With:

Lawrence Eichenfield, MD

Speakers’ Bureau: Valeant

Consultant/Advisor: Allergan; Anacor Pharmaceuticals Inc; Dignity Sciences Ltd.; Eli Lilly and Company; Galderma; Genentech, Inc.; Otsuka Pharmaceutical Co., Ltd/Medimetriks Pharmaceuticals Inc; Pfizer Inc; Ralexar Therapeutics; Regeneron Pharmaceuticals, Inc; TopMD Inc; Valeant

Grant/Research Support: Regeneron Pharmaceuticals, Inc

Jonathan I. Silverberg, MD, PhD, MPH

Speakers’ Bureau: Regeneron Pharmaceuticals, Inc

Consultant/Advisor: AbbVie Inc; Anacor Pharmaceuticals Inc; Eli Lilly and Company; Galderma; GlaxoSmithKline plc; IntraDermTM Pharmaceuticals; Kiniksa Pharmaceuticals; Menlo Therapeutics Inc; Pfizer Inc; Procter & Gamble; Realm-1; Regeneron Pharmaceuticals, Inc

Grant/Research Support: GlaxoSmithKline plc

Linda Stein-Gold, MD

Speakers’ Bureau: LEO Pharma Inc; Pfizer Inc.

Consultant/Advisor: LEO Pharma Inc

Non-faculty: Lou Settembrino; Ankita Patel, PharmD; Sandy Breslow; Leah Johnson; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and ASiM.


CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM, and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Please login or register to take this course.